Vantage Investment Partners LLC Acquires 79,441 Shares of Novo Nordisk A/S $NVO

Vantage Investment Partners LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 17.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 533,565 shares of the company’s stock after buying an additional 79,441 shares during the period. Novo Nordisk A/S accounts for about 2.0% of Vantage Investment Partners LLC’s investment portfolio, making the stock its 21st biggest holding. Vantage Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $29,608,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after purchasing an additional 2,274,925 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Novo Nordisk A/S by 101.4% during the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after purchasing an additional 1,246,467 shares during the last quarter. DAVENPORT & Co LLC boosted its holdings in Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after acquiring an additional 935,468 shares in the last quarter. Sustainable Growth Advisers LP increased its holdings in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after acquiring an additional 649,390 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Novo Nordisk A/S by 42.6% in the 2nd quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after purchasing an additional 441,034 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 5.0%

NYSE:NVO opened at $62.28 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The company’s fifty day moving average price is $51.85 and its 200-day moving average price is $54.85. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The firm has a market capitalization of $278.08 billion, a P/E ratio of 18.10 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating for the company. CICC Research began coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.